News

The Manila Times4h
BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress
Mecbotamab vedotin (Mec-V; CAB-AXL-ADC) continues to demonstrate exceptional overall survival (OS) with a 2-year landmark ...
The American Journal of Managed Care11h
Tarlatamab Safety Varies Between Clinical and Real-World SCLC Trials
The bispecific T-cell engager tarlatamab demonstrated favorable antitumor activity in a small cohort with small cell lung ...